Literature DB >> 16825483

Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.

Elaine M Quinet1, Dawn A Savio, Anita R Halpern, Liang Chen, Gertrude U Schuster, Jan-Ake Gustafsson, Mike D Basso, Ponnal Nambi.   

Abstract

The nuclear receptors liver X receptor (LXR) LXRalpha and LXRbeta are differentially expressed ligand-activated transcription factors that induce genes controlling cholesterol homeostasis and lipogenesis. Synthetic ligands for both receptor subtypes activate ATP binding cassette transporter A1 (ABCA1)-mediated cholesterol metabolism, increase reverse cholesterol transport, and provide atheroprotection in mice. However, these ligands may also increase hepatic triglyceride (TG) synthesis via a sterol response element binding protein 1c (SREBP-1c)-dependent mechanism through a process reportedly regulated by LXRalpha. We studied pan-LXRalpha/beta agonists in LXRalpha knockout mice to assess the contribution of LXRbeta to the regulation of selected target genes. In vitro dose-response studies with macrophages from LXRalpha-/- and beta-/- mice confirm an equivalent role for LXRalpha and LXRbeta in the regulation of ABCA1 and SREBP-1c gene expression. Cholesterol-efflux studies verify that LXRbeta can drive apoA1-dependent cholesterol mobilization from macrophages. The in vivo role of LXRbeta in liver was further evaluated by treating LXRalpha-/- mice with a pan-LXRalpha/beta agonist. High-density lipoprotein (HDL) cholesterol increased without significant changes in plasma TG or very low density lipoprotein. Analysis of hepatic gene expression consistently revealed less activation of ABCA1 and SREBP-1c genes in the liver of LXRalpha null animals than in treated wild-type controls. In addition, hepatic CYP7A1 and several genes involved in fatty acid/TG biosynthesis were not induced. In peripheral tissues from these LXRalpha-null mice, LXRbeta activation increases ABCA1 and SREBP-1c gene expression in a parallel manner. However, putative elevation of SREBP-1c activity in these tissues did not cause hypertriglyceridemia. In summary, selective LXRbeta activation is expected to stimulate ABCA1 gene expression in macrophages, contribute to favorable HDL increases, but circumvent hepatic LXRalpha-dominated lipogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825483     DOI: 10.1124/mol.106.022608

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

Review 1.  Liver X receptors, atherosclerosis and inflammation.

Authors:  Daryn R Michael; Tim G Ashlin; Melanie L Buckley; Dipak P Ramji
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways.

Authors:  Serena Ghisletti; Wendy Huang; Kristen Jepsen; Chris Benner; Gary Hardiman; Michael G Rosenfeld; Christopher K Glass
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

Review 3.  Liver X receptors as therapeutic targets in metabolism and atherosclerosis.

Authors:  Takashi Nomiyama; Dennis Bruemmer
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

5.  Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Authors:  Eric D Bischoff; Chris L Daige; Mary Petrowski; Harry Dedman; Jennifer Pattison; Joseph Juliano; Andrew C Li; Ira G Schulman
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

6.  Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?

Authors:  Melanie Tran; Li Wang
Journal:  Hepatology       Date:  2016-12-29       Impact factor: 17.425

Review 7.  Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

Review 8.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

9.  Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.

Authors:  Junga Lee; Richard C Scheri; Yuan Zhang; Lawrence R Curtis
Journal:  Toxicol Appl Pharmacol       Date:  2008-08-26       Impact factor: 4.219

Review 10.  Flavonoids as dietary regulators of nuclear receptor activity.

Authors:  Yishai Avior; David Bomze; Ory Ramon; Yaakov Nahmias
Journal:  Food Funct       Date:  2013-04-19       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.